Bone Solutions Reaches 1,000-Implant Milestone for OsteoCrete

Bone Solutions Inc. (BSI), an orthobiologics technology company located in Colleyville, Texas, announces it has surpassed 1,000 cases implanting OsteoCrete in various orthopedic applications.
 
“The company has now again reached a wonderful milestone. We have successfully implanted OsteoCrete in over 1,000 cases throughout the United States in various hospitals and teaching institutions,” said BSI president and CEO Drew Diaz.
 
“OsteoCrete was introduced to me at a time when I was looking for a structural bone void filler that has resorption capabilities as well as prevents subsidence of reduction while having the properties to stimulate natural bone remodeling. It delivered on these expectations and much more. The handling properties and physical characteristics are second to none. I can inject, pack, mold, and even sculpt OsteoCrete to meet any bone void filling need that I encounter in a practice of complex fracture and trauma patients,” stated Robert J. Wetzel, M.D., orthopedic trauma surgeon at University Hospitals Cleveland Medical Center and assistant professor at Case Western Reserve University.
 
OsteoCrete contains magnesium and as a result has a high compressive strength that is three times stronger than the average cancellous bone. Most of the magnesium in the body (60 percent) is stored in bone and helps to preserve and develop bone structure by working with Vitamin D and calcium. Its essential role in maintaining healthy bones was a key component of BSI’s approach to developing its OsteoCrete technology.
 
The U.S. Food and Drug Administration has cleared this orthopedic technology for use in bone-related surgical procedures ranging from complex sport-related injuries to all musculoskeletal extremities trauma cases. It was launched in September 2017.
 
Last year WishBone Medical confirmed a private label distribution agreement with Bone Solutions for worldwide rights within pediatric orthopedics to license and sell OsteoCrete.
 
“This product is the holy grail for pediatric orthopedics as the resorbable properties eliminate the need for secondary operations,” WishBone founder and CEO Nick Deeter said. “Kids already harbor a lot of anxieties around the idea of surgery. If we can save patients and their families the expense and worries of follow-up procedures, that alone is a big win.”